Memorial Sloan Kettering Cancer Center
Andrew Zelenetz, MD, PhD, is a Medical Oncologist with expertise in Hodgkin and non-Hodgkin lymphomas at the Memorial Sloan Kettering Cancer Center, New York, NY, USA, where he has also been appointed Medical Director of Quality Informatics and is Chair of the Non-Hodgkin’s Lymphoma Panel of the National Comprehensive Cancer Network (NCCN). Dr Zelenetz has been awarded the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times, as well as having received the Rodger Winn Award from the NCCN in 2012. Dr Zelenetz gained his MD from Harvard Medical School, and then went on complete a clinical fellowship and residency at Stanford University Medical Center. Dr Zelenetz is a member of several societies and has published more than 100 papers based on his intriguing research into lymphoma. He has helped to develop many of the approved agents that are currently being used to treat lymphoma, including: 131I-tosituomab/tositumomab, bortezomib and pralatrexate. Currently, his research interests lie in using computer-aided image analysis and evaluating novel combinations of agents.
Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma
Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design
m7-FLIPI identifies patients with early disease progression of FL after therapy
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL